XML 62 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity - Performance-Based Stock Units - Additional Information (Detail) - Performance Stock Units [Member] - shares
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2018
Mar. 19, 2018
Sep. 30, 2017
Mar. 31, 2018
Class of Stock [Line Items]            
Weighted average remaining vesting term           11 years 7 months 6 days
Performance Condition One [Member]            
Class of Stock [Line Items]            
Percentage of stock units to vest if stated performance condition is achieved on or before date     50.00%      
Portion of stock units subject to an FDA acceptance of the Company's NDA submission of Durasert three-year uveitis for review on or before March 31, 2018         One third One third
Number of Performance-Based Stock Units, vested       48,332    
Performance Condition Two [Member]            
Class of Stock [Line Items]            
Portion of stock units subject to an FDA approval of Durasert three-year uveitis on or before March 31, 2019         Two-thirds Two-thirds
Scenario, Forecast [Member] | Performance Condition One [Member]            
Class of Stock [Line Items]            
Percentage of stock units to vest if stated performance condition is achieved on or before date   50.00%        
Number of performance-based stock units subject to service-based vesting of one year from performance condition achievement date   48,332        
Scenario, Forecast [Member] | Performance Condition Two [Member]            
Class of Stock [Line Items]            
Percentage of stock units to vest if stated performance condition is achieved on or before date 50.00% 50.00%